Effect of Combined HCV Therapy on Natural Killer Cell Activity. 2019

Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Hepatitis C virus (HCV) is a major health problem all over the world with the highest prevalence reported in Egypt. Various treatment regimens have been developed over the last years. Interferon (IFN) based regimen was the standard of care regimen and then the IFN-free therapies were emerged. Host innate immunity through the activity of natural killer (NK) cell is one of the major players in competing infections and tumors, by producing perforin and granzymes that cause cytolysis of target cells, or by the production of various cytokines such as natural interferon gamma. Natural cytotoxicity receptors (NCRs), including Nkp30, Nkp44 and Nkp46, are a group of activating receptors that almost have restricted expression on the surface of NK cells and their density correlates with NK cytotoxicity. The role of these cells is not fully elucidated in patients with chronic HCV infection either treatment-naive or treatment experienced. Therefore, this study aimed to investigate the change that occurs in NK cell activity and cytotoxicity in response to successful elimination of HCV from blood after triple therapy with PEG-IFN-α, ribavirin and sofosbuvir. A total of 56 (50 male: 6 female) HCV patients with mean age of 41.6± 12.1 years were included in this study. They were divided into two groups: treatment naive group (20 patients) and the sustained virologic response (SVR) group (36 patients). All patients were investigated for their NK cell profile, NCRs, perforin and granzyme B expression by flow cytometry. Data was expressed as mean fluorescence intensity (MFI). Results revealed significant increase in MFI of granzyme B (P=0.001) and decrease in MFI of NKp30 (P=0.042) in the SVR group as compared to treatment naïve group. These findings indicated that triple therapy of HCV (IFN, Ribavirin and Sofosbuvir) effected NK activation and cytotoxicity.

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004534 Egypt A country in northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip, and the Red Sea north of Sudan, and includes the Asian Sinai Peninsula Its capital is Cairo. Arab Republic of Egypt,United Arab Republic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069474 Sofosbuvir A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C. 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester,GS-7977,PSI 7977,PSI-7977,PSI7977,Sovaldi,7977, PSI,GS 7977,GS7977
D000072230 Sustained Virologic Response The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS. Sustained Viral Suppression,Response, Sustained Virologic,Suppression, Sustained Viral,Sustained Viral Suppressions,Sustained Virologic Responses,Virologic Response, Sustained
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
January 1986, Archives of dermatological research,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
August 1992, Journal of applied physiology (Bethesda, Md. : 1985),
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
April 1988, Transplantation proceedings,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
June 1993, Alimentary pharmacology & therapeutics,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
November 1996, Maturitas,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
April 1995, Journal of applied physiology (Bethesda, Md. : 1985),
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
January 1988, Cancer detection and prevention,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
December 1985, Cancer,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
February 1998, The British journal of dermatology,
Elham Abd-Elsamie, and Taghreed M Kamal-ElDin, and Ashraf E Hassaballa, and Medhat A, and Eman R Badawy, and Tarek T ElMelegy, and Asmaa M Zahran, and Mohamed A Mekky
October 1995, General pharmacology,
Copied contents to your clipboard!